Acrivon Begin Period Cash Flow vs Depreciation Analysis

ACRV Stock

7.44 0.14 1.85%

Acrivon Therapeutics, financial indicator trend analysis is way more than just evaluating Acrivon Therapeutics, prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Acrivon Therapeutics, is a good investment. Please check the relationship between Acrivon Therapeutics, Begin Period Cash Flow and its Depreciation accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Acrivon Therapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

Begin Period Cash Flow vs Depreciation

Begin Period Cash Flow vs Depreciation Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Acrivon Therapeutics, Begin Period Cash Flow account and Depreciation. At this time, the significance of the direction appears to have strong relationship.

The correlation between Acrivon Therapeutics,'s Begin Period Cash Flow and Depreciation is 0.71. Overlapping area represents the amount of variation of Begin Period Cash Flow that can explain the historical movement of Depreciation in the same time period over historical financial statements of Acrivon Therapeutics, Common, assuming nothing else is changed. The correlation between historical values of Acrivon Therapeutics,'s Begin Period Cash Flow and Depreciation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Begin Period Cash Flow of Acrivon Therapeutics, Common are associated (or correlated) with its Depreciation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Depreciation has no effect on the direction of Begin Period Cash Flow i.e., Acrivon Therapeutics,'s Begin Period Cash Flow and Depreciation go up and down completely randomly.

Correlation Coefficient

0.71

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Depreciation

Depreciation indicates how much of Acrivon Therapeutics, value has been used up. For tax purposes Acrivon Therapeutics, can deduct the cost of the tangible assets it purchases as business expenses. However, Acrivon Therapeutics, Common must depreciate these assets in accordance with IRS rules about how and when the deduction may be taken, and how long it will last. The systematic allocation of the cost of a tangible asset over its useful life.

Most indicators from Acrivon Therapeutics,'s fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Acrivon Therapeutics, current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Acrivon Therapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

Selling General Administrative is likely to climb to about 22.1 M in 2024, whereas Issuance Of Capital Stock is likely to drop 0.00 in 2024.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	16.2M	32.7M	66.7M	70.0M
Cost Of Revenue	832K	1.1M	536K	680.9K

Total Operating Expenses Cost Of Revenue

Acrivon Therapeutics, fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Short Long Term Debt	Total Current Assets	Capital Stock	Net Working Capital
Total Assets		0.96	0.88	0.82	0.87	0.84	0.98	-0.68	-0.81	0.69	0.72	0.78	0.59	-0.62	0.99	0.72	0.22	0.94	0.89	0.39	0.87	0.97	-0.53	0.99	0.9	0.99
Short Long Term Debt Total	0.96		0.79	0.77	0.7	0.72	0.98	-0.86	-0.77	0.69	0.89	0.63	0.42	-0.6	0.98	0.65	0.47	0.81	0.75	0.63	0.7	0.97	-0.52	0.98	0.77	0.98
Other Current Liab	0.88	0.79		0.91	0.9	0.93	0.9	-0.42	-0.93	0.84	0.47	0.58	0.37	-0.81	0.89	0.74	-0.09	0.84	0.97	0.09	0.9	0.92	-0.64	0.89	0.97	0.88
Total Current Liabilities	0.82	0.77	0.91		0.77	0.95	0.86	-0.45	-1.0	0.98	0.53	0.41	0.17	-0.95	0.85	0.93	-0.08	0.73	0.85	0.16	0.77	0.87	-0.89	0.85	0.86	0.83
Total Stockholder Equity	0.87	0.7	0.9	0.77		0.92	0.8	-0.23	-0.78	0.63	0.29	0.84	0.71	-0.59	0.82	0.71	-0.27	0.96	0.98	-0.11	1.0	0.82	-0.48	0.82	0.98	0.81
Net Tangible Assets	0.84	0.72	0.93	0.95	0.92		0.83	-0.3	-0.95	0.87	0.37	0.62	0.42	-0.85	0.83	0.92	-0.26	0.87	0.94	-0.04	0.92	0.85	-0.79	0.83	0.95	0.82
Property Plant And Equipment Net	0.98	0.98	0.9	0.86	0.8	0.83		-0.74	-0.86	0.77	0.78	0.65	0.43	-0.71	1.0	0.72	0.29	0.86	0.87	0.47	0.8	1.0	-0.59	1.0	0.88	0.99
Net Debt	-0.68	-0.86	-0.42	-0.45	-0.23	-0.3	-0.74		0.44	-0.43	-0.99	-0.28	-0.1	0.34	-0.74	-0.32	-0.85	-0.41	-0.32	-0.94	-0.23	-0.72	0.29	-0.74	-0.34	-0.75
Retained Earnings	-0.81	-0.77	-0.93	-1.0	-0.78	-0.95	-0.86	0.44		-0.97	-0.51	-0.41	-0.17	0.95	-0.84	-0.91	0.09	-0.74	-0.87	-0.14	-0.78	-0.88	0.88	-0.85	-0.88	-0.83
Accounts Payable	0.69	0.69	0.84	0.98	0.63	0.87	0.77	-0.43	-0.97		0.5	0.2	-0.05	-0.99	0.75	0.9	-0.06	0.57	0.74	0.18	0.63	0.79	-0.94	0.75	0.75	0.73
Cash	0.72	0.89	0.47	0.53	0.29	0.37	0.78	-0.99	-0.51	0.5		0.31	0.12	-0.41	0.78	0.41	0.8	0.46	0.37	0.91	0.29	0.76	-0.38	0.78	0.4	0.79
Non Current Assets Total	0.78	0.63	0.58	0.41	0.84	0.62	0.65	-0.28	-0.41	0.2	0.31		0.96	-0.12	0.69	0.42	-0.04	0.92	0.74	0.03	0.84	0.64	-0.08	0.68	0.74	0.71
Non Currrent Assets Other	0.59	0.42	0.37	0.17	0.71	0.42	0.43	-0.1	-0.17	-0.05	0.12	0.96		0.12	0.48	0.22	-0.11	0.79	0.57	-0.09	0.71	0.42	0.15	0.47	0.57	0.5
Other Assets	-0.62	-0.6	-0.81	-0.95	-0.59	-0.85	-0.71	0.34	0.95	-0.99	-0.41	-0.12	0.12		-0.67	-0.87	0.14	-0.5	-0.71	-0.09	-0.59	-0.73	0.94	-0.68	-0.71	-0.65
Cash And Short Term Investments	0.99	0.98	0.89	0.85	0.82	0.83	1.0	-0.74	-0.84	0.75	0.78	0.69	0.48	-0.67		0.72	0.29	0.88	0.87	0.46	0.82	1.0	-0.57	1.0	0.88	1.0
Common Stock Shares Outstanding	0.72	0.65	0.74	0.93	0.71	0.92	0.72	-0.32	-0.91	0.9	0.41	0.42	0.22	-0.87	0.72		-0.19	0.7	0.74	0.06	0.71	0.73	-0.93	0.72	0.75	0.71
Non Current Liabilities Total	0.22	0.47	-0.09	-0.08	-0.27	-0.26	0.29	-0.85	0.09	-0.06	0.8	-0.04	-0.11	0.14	0.29	-0.19		-0.06	-0.2	0.97	-0.27	0.26	0.16	0.29	-0.17	0.3
Other Current Assets	0.94	0.81	0.84	0.73	0.96	0.87	0.86	-0.41	-0.74	0.57	0.46	0.92	0.79	-0.5	0.88	0.7	-0.06		0.93	0.09	0.96	0.86	-0.43	0.88	0.93	0.89
Other Stockholder Equity	0.89	0.75	0.97	0.85	0.98	0.94	0.87	-0.32	-0.87	0.74	0.37	0.74	0.57	-0.71	0.87	0.74	-0.2	0.93		-0.03	0.98	0.88	-0.56	0.87	1.0	0.86
Total Liab	0.39	0.63	0.09	0.16	-0.11	-0.04	0.47	-0.94	-0.14	0.18	0.91	0.03	-0.09	-0.09	0.46	0.06	0.97	0.09	-0.03		-0.11	0.43	-0.09	0.46	0.0	0.47
Net Invested Capital	0.87	0.7	0.9	0.77	1.0	0.92	0.8	-0.23	-0.78	0.63	0.29	0.84	0.71	-0.59	0.82	0.71	-0.27	0.96	0.98	-0.11		0.82	-0.48	0.82	0.98	0.81
Property Plant And Equipment Gross	0.97	0.97	0.92	0.87	0.82	0.85	1.0	-0.72	-0.88	0.79	0.76	0.64	0.42	-0.73	1.0	0.73	0.26	0.86	0.88	0.43	0.82		-0.6	1.0	0.9	0.99
Short Long Term Debt	-0.53	-0.52	-0.64	-0.89	-0.48	-0.79	-0.59	0.29	0.88	-0.94	-0.38	-0.08	0.15	0.94	-0.57	-0.93	0.16	-0.43	-0.56	-0.09	-0.48	-0.6		-0.57	-0.57	-0.55
Total Current Assets	0.99	0.98	0.89	0.85	0.82	0.83	1.0	-0.74	-0.85	0.75	0.78	0.68	0.47	-0.68	1.0	0.72	0.29	0.88	0.87	0.46	0.82	1.0	-0.57		0.88	1.0
Capital Stock	0.9	0.77	0.97	0.86	0.98	0.95	0.88	-0.34	-0.88	0.75	0.4	0.74	0.57	-0.71	0.88	0.75	-0.17	0.93	1.0	0.0	0.98	0.9	-0.57	0.88		0.87
Net Working Capital	0.99	0.98	0.88	0.83	0.81	0.82	0.99	-0.75	-0.83	0.73	0.79	0.71	0.5	-0.65	1.0	0.71	0.3	0.89	0.86	0.47	0.81	0.99	-0.55	1.0	0.87

Click cells to compare fundamentals

Acrivon Therapeutics, Account Relationship Matchups

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Acrivon Stock Analysis

When running Acrivon Therapeutics,'s price analysis, check to measure Acrivon Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acrivon Therapeutics, is operating at the current time. Most of Acrivon Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Acrivon Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acrivon Therapeutics,'s price. Additionally, you may evaluate how the addition of Acrivon Therapeutics, to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Acrivon Begin Period Cash Flow vs Depreciation Analysis

Begin Period Cash Flow vs Depreciation

Begin Period Cash Flow vs Depreciation Correlation Analysis

Correlation Coefficient

Begin Period Cash Flow

Depreciation

Acrivon Therapeutics, fundamental ratios Correlations

Acrivon Therapeutics, Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Acrivon Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Invested Capital	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 1.0	Property Plant And Equipment Net
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Total Current Assets	+ 1.0	Property Plant And Equipment Net
Property Plant And Equipment Gross	+ 1.0	Cash And Short Term Investments
Total Current Assets	+ 1.0	Cash And Short Term Investments

Retained Earnings	- 1.0	Total Current Liabilities
Other Assets	- 0.99	Accounts Payable
Cash	- 0.99	Net Debt
Accounts Payable	- 0.97	Retained Earnings
Retained Earnings	- 0.95	Net Tangible Assets
Other Assets	- 0.95	Total Current Liabilities